ArticleDrug design, development and therapy2025
P2Y12R Blockade Attenuates LPS-Induced Acute Lung Injury Associated with Suppression of Inflammasome-Mediated Pyroptotic Signaling.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Acute lung injury (ALI) is characterized by excessive inflammation and cell death, with no specific pharmacological treatment. P2Y12 receptor (P2Y12R) is implicated in regulating inflammation, but their role in ALI remains unclear. This study investigates the effects of P2Y12R antagonists including Clopidogrel, Prasugrel, and Ticagrelor on LPS-induced ALI in mice, focusing on inflammation and pyroptosis. Methods: Mice were pre-treated with P2Y12R antagonists before LPS administration. Lung injury was assessed via histology, wet/dry ratio, myeloperoxidase (MPO) activity, and inflammatory cytokine levels in bronchoalveolar lavage fluid (BALF). Gene and protein levels of IL-1β, IL-6, TNF-α, and inflammasome components (NLRP3, ASC, Caspase-1, GSDMD) were measured. Ultrastructural changes were analyzed by transmission electron microscopy (TEM). Results: P2Y12R antagonists reduced histological injury, pulmonary edema, and inflammatory cytokines in BALF, with Ticagrelor showing the most prominent effects. Gene and protein levels of IL-1β, IL-6, and TNF-α were decreased. P2Y12R antagonists also inhibited inflammasome activation and pyroptosis. TEM analysis showed reduced organelle damage in treated groups. Conclusion: P2Y12R antagonists, particularly Ticagrelor, attenuate lung injury and were associated with suppression of the NLRP3/caspase-1/GSDMD pyroptotic signaling axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.